Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer - Netherlands
doi 10.1016/j.bbcan.2014.07.007
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It

Clinical Medicine Insights: Oncology
Oncology
2016English

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer

International Journal of Breast Cancer
Cancer ResearchOncologyPharmacology
2012English

Resistance to Trastuzumab in HER2-Positive Mucinous Invasive Ductal Breast Carcinoma

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Src, a Potential Target for Overcoming Trastuzumab Resistance in HER2-positive Breast Carcinoma

British Journal of Cancer
Cancer ResearchOncology
2014English

Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib

AboutOpen
2018English

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Pcn20 - Contribution of Trastuzumab to the Prognostic Improvement of Her2-Positive Early Breast Cancer in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy